Neuronal polarity is essential for the proper development, growth, and physiology of neurons. Within neurons, microtubules (MTs) and motor protein polarities are required for establishing and maintaining neuronal polarity. However, unanswered questions remain: 1. Why are some cytoplasmic molecules in axons but not dendrites? 2. How do MAPs become compartmentalized differently in each type of neurite? 3. Why does a neuron have a single axon but multiple dendrites?⁵

To help you, the researcher, to answer these questions (as well as many others regarding MT functions in the central nervous system!) for a number of years now we’ve been providing a reliable range of kits by Cytoskeleton Inc. Their highly useful reagents include the Signal-Seeker Enrichment kits for quantifying levels of endogenous PTMs such as acetylation, tyrosine phosphorylation, ubiquitination, and SUMOylation, as well as purified cytoskeletal proteins (e.g., actins, tubulins, kinesin and dynein motors) and functional assay kits to measure the activities of these same proteins.

Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor  (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.

Mass spectrometry is a technology which is widely used in most scientific disciplines that require accurate and precise measurement of elemental and molecular components. Its use in the pharmaceutical sector is often associated with the Drug Discovery and Development process. The primordial step to analyze a sample is to perform a sample treatment to enable its study. It really requires know-how to obtain good quality results. The following tips and tricks can help you to rapidly select a protein purification strategy and to anticipate some possible problems.

mRNA vaccines are developing very quickly. There are already 25 ongoing clinical trials against cancers, as well as clinical trials against infectious diseases such as HIV. Recombinant monoclonal antibody (mAB) based treatments that have lead to the most successful therapies could even switch to mRNA coding heavy and light chains for direct antibody production into the patient (as of yet still at the level of mouse models).

Indeed, messenger RNAs (mRNA) are now new biological entities to take in consideration for the development of efficient and personalized therapies. They have several advantages over conventional drugs: